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Use of topical glucocorticoid for inflammatory skin conditions is limited by systemic and local side-
effects. This investigation addressed the hypothesis that topical 5a-tetrahydrocorticosterone (5aTHB, a
corticosterone metabolite) inhibits dermal inflammation without affecting processes responsible for skin
thinning and impaired wound healing. The topical anti-inflammatory properties of 5aTHB were com-
pared with those of corticosterone in C57Bl/6 male mice with irritant dermatitis induced by croton oil,
whereas its effects on angiogenesis, inflammation, and collagen deposition were investigated by subcu-
taneous sponge implantation. 5aTHB decreased dermal swelling and total cell infiltration associated with
dermatitis similarly to corticosterone after 24 h, although at a five fold higher dose, but in contrast did
not have any effects after 6 h. Pre-treatment with the glucocorticoid receptor antagonist RU486 attenu-
ated the effect of corticosterone on swelling at 24 h, but not that of 5aTHB. After 24 h 5aTHB reduced
myeloperoxidase activity (representative of neutrophil infiltration) to a greater extent than corticos-
terone. At equipotent anti-inflammatory doses 5aTHB suppressed angiogenesis to a limited extent, unlike
corticosterone which substantially decreased angiogenesis compared to vehicle. Furthermore, 5aTHB
reduced only endothelial cell recruitment in sponges whereas corticosterone also inhibited smooth mus-
cle cell recruitment and decreased transcripts of angiogenic and inflammatory genes. Strikingly, corticos-
terone, but not 5aTHB, reduced collagen deposition. However, both 5aTHB and corticosterone attenuated
macrophage infiltration into sponges. In conclusion, 5aTHB displays the profile of a safer topical anti-
inflammatory compound. With limited effects on angiogenesis and extracellular matrix, it is less likely
to impair wound healing or cause skin thinning.
 2017 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Inflammatory skin disease is highly prevalent worldwide:
according to estimates published in 2012, eczema affects approxi-
mately 230 million people globally, and topical anti-inflammatory
glucocorticoids are the most common treatment [1]. However, the
therapeutic benefits of these drugs are offset by severe side-effects
[2].
Following application of glucocorticoids to the skin, adverse
effects manifest locally (skin atrophy and impaired wound healing)and systemically (e.g. osteoporosis, abdominal obesity, and glau-
coma) [3]. Skin atrophy is characterised by increased transparency
and striae, due to suppression of cell proliferation and inhibition of
collagen synthesis, whereas delayed wound healing is attributed to
dysregulation of keratinocyte proliferation, fibroblastic activity,
and angiogenesis causing delayed formation of granulation tissue
[4,5]. These factors restrict the use of more potent glucocorticoids
and also the length of treatment, particularly in vulnerable patients
such as infants and the elderly. Accordingly, novel drugs or deliv-
ery modes have been sought to improve the therapeutic index of
topical steroids. This may be achieved by ‘‘dissociated glucocorti-
coids” which invoke trans-repression through the glucocorticoid
receptor (GR) without trans-activation [6].
5a-Tetrahydrocorticosterone (5aTHB) is a naturally occurring
glucocorticoid metabolite, formed by reduction of the A-ring of
74 A. Gastaldello et al. / Biochemical Pharmacology 129 (2017) 73–84corticosterone, the principle endogenous glucocorticoid in rodents.
Two 5a-reductase isozymes catalyse the rate-determining step in
5aTHB synthesis from corticosterone: the type I isozyme is
expressed in the liver, kidney and skin; the type II isozyme is
expressed principally in the liver, genital tract, prostate and skin.
Recent studies have suggested that 5aTHB exhibits a dissociated
profile of action, possibly acting through GR. 5aTHB displayed
anti-inflammatory properties when administered subcutaneously
in mice subjected to thioglycollate-induced peritonitis, but did
not induce the chronic adverse metabolic changes (such as
increased insulin and body mass) produced by corticosterone [7].
5aTHB and corticosterone suppressed infiltration of neutrophils
into the inflamed peritoneum to a similar extent, but 5aTHB had
a lesser effect on macrophage recruitment, suggesting a different
profile of action. When infused systemically, 5aTHB demonstrated
rapid clearance from the systemic circulation [7], likely limiting its
oral use, but the same characteristic would be beneficial in topical
treatments in which systemic effects are unwanted.
This investigation addressed the hypothesis that topical 5aTHB
can effectively reduce skin inflammation through a GR-dependent
mechanism, but with limited effects on processes such as angio-
genesis and collagen deposition, the inhibition of which underpin
most common problems associated with topical glucocorticoid
therapy. The efficacy of topical 5aTHB application for treating skin
inflammation was compared with that of corticosterone in vivo
using croton oil-induced dermatitis and the role of GR was
assessed by pre-administration of the GR antagonist mifepristone
(RU486). This is a steroid-responsive model of dermal inflamma-
tion, driven primarily by neutrophil accumulation, commonly used
for testing anti-inflammatory treatments for irritant dermatitis
[8,9]. An in vivomodel of sponge implantation allowed comparison
of the effects of corticosterone and 5aTHB on inflammation, angio-
genesis and collagen deposition.2. Materials and methods
2.1. Materials
Chemicals were from Sigma Aldrich (Poole, UK) unless other-
wise stated. Steroids (corticosterone, 5aTHB and RU486) were
from Steraloids (Newport, RI, USA).
2.2. Animal welfare, models and ethical statements
Male mice (C57BL/6, 8–10 week old) were from Harlan Labora-
tories (Shardlow, UK). Animals were allowed to acclimatise for one
week prior to experimentation, maintained under controlled
conditions of light (lights on 0700–1900 h) and temperature
(18–20 C) and allowed free access to standard chow (Special Diet
Services, Witham, UK) and drinking water. All experimental proce-
dures were performed under UK Home Office guidelines.
2.2.1. In vivo model of irritant dermatitis
Mice were treated on the inner surface of the right ear with
either croton oil only (COmixture: 10 lL, 3% v/v in ethanol and iso-
propyl myristate 30:5) or with solutions of corticosterone or
5aTHB diluted in the CO mixture; the left ear was untreated. The
EC50 dose of corticosterone to reduce swelling was determined per-
forming dose-response experiments (0.3–30 lg; 6 h, n = 4/group;
24 h, 8–12/group) in which a ‘‘non-linear log(agonist) versus
response (three parameters)” regression curve was fitted using
GraphPad 6 software (La Jolla, CA, USA). Subsequently, the efficacy
of 5aTHB was compared using doses corresponding to 1, 3 and 5
times the EC50 of corticosterone after 6 h (corticosterone, 10 lg;
5aTHB, 10–50 lg; n = 4–8/group) or 24 h (corticosterone, 5 lg;5aTHB, 5–25 lg; n = 8–12/group). Mice were culled by asphyxia-
tion with carbon dioxide and ears excised and wet weighed.
Inflammatory swelling was evaluated as the wet weight difference
between treated and untreated ears, and the effect of steroids is
presented as a percentage of the response to CO alone (mean
weight difference = 100%).2.2.2. In vivo model of irritant dermatitis and treatment with RU486 in
adrenalectomised mice
Male mice (n = 6–11/group) were injected, prior to treatment
with steroids, with the GR antagonist RU486. Adrenalectomised
mice were used to avoid the influence of increased physiological
levels of glucocorticoids due to stress responses.2.2.2.1. Surgery. Bilateral adrenalectomy surgery was performed
through dorsal incisions, under isoflurane anaesthesia (Merial,
Harlow, UK). After surgery, animals were maintained on 0.9% saline
drinking water to maintain fluid and electrolyte balance and
allowed to recover for one week before subsequent intervention.2.2.2.2. RU486 treatments. RU486 (0.5 mg/mouse; 25 lL, 20 mg/mL
in ethanol (vehicle)) was injected subcutaneously into mice 15 min
prior to any topical treatment. Contact irritant dermatitis was
induced and steroid treatment applied (24 h) as described in
Section 2.2.1.2.2.3. In vivo model of inflammatory angiogenesis
An autoclaved cubic polyurethane sponge (0.5 cm3; grade
XE1700V, Caligen Foam Ltd., Accrington, U.K.) was implanted
sub-cutaneously on each flank of mice anaesthetised with isoflu-
rane (Merial, Harlow, UK). For the delivery of steroids, one silastic
pellet (Silastic 20 medical grade, Dow Corning, Midland, USA)
impregnated with vehicle (silastic only), corticosterone (3 mg/pel-
let) or 5aTHB (3 or 15 mg/pellet) was inserted in each sponge. Val-
idation of the preparation and release properties of these pellets
has been reported [10]. Each animal in the treatment groups had
an intervention-impregnated sponge (corticosterone or 5aTHB)
implanted on the right side, and a vehicle sponge on the left. Ani-
mals in the control group had vehicle sponges implanted on each
side. 21 days after surgery, mice were euthanized, sponges excised
and pellets removed. Sponges were bisected and one half was pre-
served in 10% formalin (in PBS) and the other immersed in RNAla-
ter solution.2.3. Laboratory analysis
2.3.1. Histological analysis
Paraffin-embedded ear tissue and sponge slices (5 lm) were re-
hydrated and stained with haematoxylin and eosin (H&E) or with
Picrosirius red solution (PRS) for collagen content analysis
(sponges only), prior to dehydration and mounting. Images were
captured using the software QCapture Pro 7 (QImaging, Canada).
On H&E stained ear sections the width of the dermis (in lm) and
cell infiltration (number of nuclei) were assessed as further mea-
surements of swelling and inflammation at both sides of the cen-
tral cartilage layer. For each parameter three different areas were
analysed and the mean value calculated.2.3.2. Quantitation of neutrophils by myeloperoxidase activity
Myeloperoxidase (MPO) activity in ear tissue was quantified
using a fluorometric detection kit (ENZO Life Sciences (Exeter,
UK)).
Table 1
Assay details for real-time PCR of murine samples. UPL denotes Universal Probe
Library fluorescent probe number (Roche Diagnostics Ltd, Burgess Hill, UK). Gene
names: Acta2 = actin, alpha 2, smooth muscle; Anxa1 = annexin A1; Ccl4 = chemokine
(C-C motif) ligand 4; Col1a1, Col1a2, Col3a1, Col4a1 = collagen, type 1-3-4, alpha 1-2;
Cxcl = chemokine (C-X-C motif) ligand; Dusp1 = dual specificity phosphatase 1; E-
selectin = selectin, endothelial; Gapdh = glyceraldehyde 3-phosphate dehydrogenase;
Icam = intercellular adhesion molecule; Il = interleukin; Ifnc = interferon gamma; L-
selectin = selectin, lymphocytes; Mcp1 = monocyte chemoattractant protein 1;
Mmp = matrix metallopeptidase; Pecam1 = platelet/endothelial cell adhesion mole-
cule 1; P-selectin = selectin, platelets; Tbp = TATA-binding protein: Timp2 = tissue
inhibitor of metalloproteinase 2; Tnf a = tumour necrosis factor alpha; VE-cad-
herin = vascular-endothelial cadherin; Vcam1 = vascular cell adhesion molecule 1;
Vegfa = vascular endothelial growth factor alpha; Vegfr2 = vascular endothelial
growth factor receptor 2.
Gene Symbol Forward primer Reverse Primer UPL
Acta2 ctctcttccagccatctttcat tataggtggtttcgtggatgc 58
Anxa1 ctttgccaagccatcctg tgggatgtctagtttccacca 21
Ccl4 ccagcagtctttgctccaa gctcactggggttagcaca 34
Col1a1 acctaagggtaccgctgga tccagcttctccatctttgc 19
Col1a2 cacctggtcctgttggaagt caccagggaagccagtca 9
Col3a1 tcccctggaatctgtgaatc tgagtcgaattggggagaat 49
Col4a1 agttggaggaatgggcttg ccagggacaccctgtgag 80
Cxcl1 gactccagccacactccaac tgacagcgcagctcattg 83
Cxcl2 ccctggttcagaaaatcatcc cttccgttgagggacagc 63
Dusp1 tggttcaacgaggctattgac ggcaatgaacaaacactctcc 89
E-selectin acagcagggcaacatgaaat caactggacccattttggaa 48
FilaminA tccctcagtcctttcaggtg gcactttgacctgcagtgg 78
Gapdh aggcaaaagacaccgtcaag agaagatgcggctgtctctg 52
Icam1 ttggagctagcggaccag ccggagctgaaaagttgtaga 80
Icam2 gcactcggagagtctcaaca gctgcagcttcagtgtgact 75
Il1b tgtaatgaaagacggcacacc tcttctttgggtattgcttgg 78
Il6 gctaccaaactggatataatcagga ccaggtagctatggtactccagaa 6
Ifnc ctcaggaagcggaaaagga aaaattcaaatagtgctggcaga 60
Keratin6 gccaaggcagacagtctaaca caggctacggttgttgtcc 55
L-selectin tggtcatctccagagccaat gcagtccatggtacccaact 47
Mcp1 catccacgtgttggctca gatcatcttgctggtgaatgagt 62
Mmp2 tgcagggtggtggtcatag tcacgctcttgagactttgg 78
Mmp9 cagaggtaacccacgtcagc gggatccaccttctgagactt 7
Mmp10 gagtctggctcatgcctacc caggaataagttggtccctga 81
Pecam1 cggtgttcagcgagatcc actcgacaggatggaaatcac 45
P-selectin agcgttgcaatgtccagagt ggatccgagcagttcacct 48
Tbp gggagaatcatggaccagaa gatgggaattccaggagtca 97
Timp2 aggtaccagatgggctgtga gtccatccagaggcactcat 52
Tnfa ttgagatccatgccgttg ctgtagcccacgtcgtagc 25
VE-cadherin tcaccttctgtgaggagatgg gatgatcagcaaggtaatcactgt 6
Vcam1 tcttacctgtgcgctgtgac gacctccacctgggttctct 47
Vegfa aaaaacgaaagcgcaagaaa tttctccgctctgaacaagg 1
Vegfr2 accagagaccctcgttttca catttgcttgcaggaggttt 22
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collagen content in sponges
For each sponge section vessels were counted in three different
areas at magnification 100X. Vessels in sections stained with H&E
were recognized by their round appearance and the presence of
erythrocytes in the lumen. Vessels identified in sections immunos-
tained for CD31 and aSMA marker were counted. The numbers of
newly formed vessels and vessels positive for either CD31 or aSMA
are represented as percentage of the vehicle group (mean
value = 100%). Macrophages were counted as the number of cells
positive for the marker F4/80 and expressed as a proportion of
the total number of cells (blue nuclei; magnification 200X). PRS
staining was quantified calculating the number of red pixels at a
magnification of 100X using ImageJ software (NIH, USA).
2.3.4. Immunostaining for CD31, aSMA and F4/80 in sponges
Immunostaining of sponge slices was performed using a Leica
Staining Robot with robotic antigen retrieval for F4/80 using tryp-
sin solution (0.5 mg/mL in PBS, 10 min, 37 C), or for aSMA manual
antibody retrieval using a pressure cooker under standard condi-
tions (citrate NCL pH 6 buffer); antigen retrieval was not per-
formed for CD31. For F4/80 and aSMA, samples were blocked
(5 min) with hydrogen peroxide solution from the Leica Refine
Detection Kit (Leica Biosystems, Milton Keynes, UK) followed by
serum block (30 min; F4/80, Immpress anti-rat (mouse absorbed)
kit (Vector Laboratories, Peterborough, UK); aSMA, Mouse on
Mouse Abcam Kit (Cambridge, UK)). Thereafter, samples were
incubated with primary antibody (30 min; F4/80 1:300 (eBio-
sciences, Hatfield, UK); aSMA 1:4000 (Sigma-Aldrich, Dorset,
UK)) prior to incubation with polymer (30 min, F4/80 Impress Kit
as above; aSMA as above). For CD31 a Leica Refine Kit (as above)
was used, which included a hydrogen peroxide block (5 min), pri-
mary antibody (120 min, 1:200 (Abcam)) and polymer incubation
(15 min). Immunostaining was completed with incubation with
3,30-diaminobenzidine (10 min) and counterstaining with haema-
toxylin (5 min), both from the Leica Refine Kit.
2.3.5. Total RNA extraction and PCR
Total RNAwas extracted fromears and sponges using the RNeasy
Fibrous Tissue Mini Kit, and first strand cDNA synthesis was per-
formed using the QuantiTect Reverse Transcription kit (Qiagen
Ltd, West Sussex, UK). Real-time quantitative PCR was performed
using a LightCycler480 (Roche Diagnostics, Mannheim, Germany)
with primers (6 pmol each, Table 1), corresponding 50 FAM-
labelled probe (UPL, 2 pmol) and LightCycler480 Probes Master
[11]. Data were normalized for the mean of the transcript abun-
dance of twohousekeeping genes, TATA-bindingprotein and glycer-
aldehyde 3-phosphate dehydrogenase, the abundances ofwhich did
not differ between groups, and represented as percentage of the
respective control group whose mean value was set to 100%.
2.4. Data analysis
All data were analysed using GraphPad Prism6 software and
presented as mean ± SEM, using statistical tests as indicated. Sig-
nificant differences were reported when p 6 0.05. For histological
analysis, the operator was blinded to treatment.3. Results
3.1. 5aTHB reduces croton oil-induced inflammation with a different
time course than corticosterone
Increasing concentrations of corticosterone reduced croton oil-
induced ear swelling in a dose-dependent manner after 6 and 24 h(Fig. 1a, b), with EC50 doses of 10 lg at 6 h and 5 lg at 24 h. 5aTHB
reduced swelling at 24 h (EC50 dose: 25 lg) but not at 6 h (Fig. 2a–
d). Only samples treated with the highest doses of 5aTHB (50 lg at
6 h and 25 lg at 24 h) were subject to further analysis.
Histological and biochemical analyses showed that croton oil-
induced swelling was accompanied by enlargement of the dermal
layer at both 6 and 24 h (Fig. 2a, b, e, f), cell infiltration (Fig. 2g–i)
and increased MPO activity (Fig. 2j, k). Application of corticos-
terone reduced dermal width at 6 and 24 h but 5aTHB only had
this effect at 24 h (Fig. 2a, b, e, f). Corticosterone and 5aTHB
reduced cell accumulation to a similar extent at 24 h, although cor-
ticosterone also had this effect after only 6 h (Fig. 2h, i). Moreover,
5aTHB was more effective than corticosterone in suppressing MPO
activity, an indicator of neutrophil activity, after 24 h, but did not
have any effect at 6 h (Fig. 2j, k).
The involvement of GR in mediating the anti-inflammatory
effects of corticosterone and 5aTHB was tested in adrenalec-
tomised mice injected with the GR antagonist RU486. Neither
adrenalectomy nor ethanol nor RU486 injection influenced the
extent of CO-induced swelling (Fig. 3a). Injection of RU486 attenu-
ated the anti-inflammatory effect of corticosterone but not that of
5aTHB (Fig. 3b).
Fig. 1. Corticosterone reduced croton oil-induced swelling in mouse ears in a dose-dependent manner at 6 and 24 h in a model of irritant dermatitis. Reduction in
inflammatory swelling by increasing dose (lg) of corticosterone after (a) 6 and (b) 24 h of treatment with croton oil (6 h, n = 4/group; 24 h, n = 8–12/group). Data are
mean ± SEM. Corticosterone was applied to mouse ears in a volume of 10 lL vehicle.
Fig. 2. Corticosterone (B) and 5a-tetrahydrocoticosterone (THB) reduced swelling, dermal width, cell infiltration and myeloperoxidase (MPO) activity in mouse ears with a
different time course in a model of croton oil (CO)-induced irritant dermatitis. Representative images of ear tissue stained with H&E showing inflammatory swelling and
changes in dermal thickness (a and b) and cell infiltration (g) after treatment with CO alone or together with steroids for 6 or 24 h, as indicated; c = cartilage & d = dermis.
Magnification = 100x and 400x as indicated on the images; green arrows in (g) point to cell nuclei of infiltrating cells. Quantification of swelling (c, d), dermal thickness (e, f),
cell number (h, i) and MPO activity (j, k) in ears of mice after treatment for 6 or 24 h with CO alone or combined with steroids as indicated. CTRL = control ears. In (j) a
representative high magnification (1000x) image of neutrophils (red arrows) in a blood vessel of a CO-treated ear is provided. The dose of each steroid in the figure refers to
the total dose applied to the mouse ear in a volume of 10 lL; B 5/10 = B 5/10 lg, THB 5/10/15/25/30/50 = 5aTHB 5–50 lg; data (mean ± SEM) were analysed by one-way
ANOVA followed by Tukey’s post hoc test; in (c) n = 4–8/group, in (d) n = 8–12/group; in (e), (f), (h), (i), (j) and (k) n = 6–10 tissue sections/group; p 6 0.05,  vs CTRL, # vs CO,
* vs B.
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inflammatory responses, altered vascular permeability and extra-
cellular matrix (ECM) regulation, with the exception of AnxA1
(Fig. 4a–c). Corticosterone reduced abundance of Ifnc, Vegfa,Pecam1, Icam1, Icam2, P- and L-selectin, Mmp9, Keratin6 and Col4a1
and increased abundance of AnxA1 compared to the group receiv-
ing croton oil alone. 5aTHB caused similar changes to those of cor-
ticosterone, with the exception of Icam2, L-selectin, Mmp9 and
Fig. 3. The glucocorticoid receptor antagonist RU486 attenuated the anti-inflammatory effect of corticosterone (B) but not of 5a-tetrahydrocoticosterone (THB) on croton oil
(CO)-induced ear swelling at 24 h in a model of irritant dermatitis in adrenalectomised (ADX) mice. (a) Comparable swelling (mg) induced by CO in ears of non-ADX versus
ADX mice treated with CO alone or in combination with ethanol (vehicle, EtOH) or RU486. (b) CO-induced ear swelling in ADX mice treated either with CO alone or together
with steroids after injection of either EtOH or RU486. Numbers after steroid refer to the total dose in lg applied to the ear in a volume of 10 lL. Data (mean ± SEM) were
analysed by one-way ANOVA followed by Tukey’s post hoc test; n = 7–11/group; p 6 0.05, # vs CO + EtOH, * vs CO + RU486, £ vs CO + B5 + EtOH.
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transcripts of the anti-inflammatory gene Dusp1 and decreased
those of Vcam1.
3.2. 5aTHB and corticosterone have discrepant effects on de novo
angiogenesis in sponges
Sponges containing vehicle pellets (V) were bright red, suggest-
ing extensive vascularization, whereas those with corticosterone
pellets (3 mg) were pale (similar to pre-implantation sponges)
indicating less vascularization (Fig. 5a). Sponges with 5aTHB
(3 mg) had a similar appearance to vehicle-treated sponges,
whereas those with 15 mg 5aTHB were somewhat paler, although
the lack of vascularization was not as extensive as that shown by
sponges containing corticosterone.
Vessels were identified by H&E staining (Fig. 5b), and
immunoreactivity for CD31 (Fig. 5c) and aSMA (Fig. 5d) associated
with vascular structures. Quantification showed that corticos-
terone dramatically reduced vessel density whether assessed by
H&E (Fig. 5e), CD31 (Fig. 5f) or aSMA (Fig. 5g) staining. In contrast,
an equivalent dose (3 mg) of 5aTHB in sponges had little effect on
vascular density (Fig. 5e, f, g). The higher dose (15 mg: equipotent
in anti-inflammatory model) reduced vascular density assessed by
H&E (Fig. 5e) and CD31 (Fig. 5f) staining but less dramatically than
with corticosterone. Strikingly, 5aTHB had little effect on the den-
sity of aSMA positive vessels (Fig. 5g). Macrophage infiltration of
sponges was observed (Fig. 6a, c) and was reduced following treat-
ment with corticosterone or 5aTHB, although this did not achieve
significance at the lower dose of 5aTHB (Fig. 6c). Collagen staining
(Fig. 6b, d) was lower in sponges treated with corticosterone, com-
pared with vehicle-treated controls, whereas 5aTHB had no effect
at either concentration.
Corticosterone treatment was associated with increased tran-
scripts for Vegfa and Vcam1 whereas transcripts for Vegfr2, Icam1,
Pecam1 (CD31), VE-cadherin, E-selectin and Acta2 (aSMA) were
decreased (Fig. 7a). In contrast, 5aTHB only decreased transcripts
of Pecam1. Corticosterone reduced the transcript abundance for
the inflammatory genes Tnfa, Il1b and Ifnc but had no effect on
Mcp1 or Il6 (Fig. 7b). In contrast, neither concentration of 5aTHB
reduced any of the gene transcripts, with the lower concentration
(3 mg) in fact increasing the abundance of transcripts for Mcp1
(Fig. 7b). In sponges containing corticosterone, transcripts for
two matrix metalloproteinases (Mmp2; Mmp10) and four collagentypes (Cola1a1, Col1a2, Col3a1, Col4a1) were reduced compared to
vehicle (Fig. 7c) but tissue inhibitor of metalloproteinases (Timp1)
and matrix metalloproteinase Mmp9 was unchanged. In contrast,
5aTHB (3 mg & 15 mg) had limited effects, only decreasing Col1a2.4. Discussion
Anti-inflammatory properties, but a safer systemic side effect
profile, of 5aTHB, an A-ring reduced metabolite of corticosterone,
have been demonstrated previously in vivo in a murine model of
thioglycollate-induced peritonitis [7]. This investigation addressed
the hypotheses that 5aTHB has advantages over conventional glu-
cocorticoids as a topical treatment for irritant dermatitis, and that
its actions are mediated through GR. 5aTHB was demonstrated to
be an effective topical anti-inflammatory agent in an in vivo model
of irritant dermatitis induced by croton oil, with effects mainly on
pathways regulating vascular permeability to cell infiltration
rather than suppression of pro-inflammatory markers. However,
experiments using the GR antagonist RU486 suggested these
effects may not be mediated by occupation of GR. Furthermore,
in comparison with corticosterone, use of 5aTHB may be associ-
ated with fewer adverse local effects (less inhibition of angiogene-
sis and collagen deposition).
The direct suppression of inflammation by topical 5aTHB was
assessed using croton oil-induced irritant dermatitis, a well-
characterised, steroid-responsive model, used extensively in the
pharmaceutical industry [6,12–14]. Croton oil promotes the
release of cytokines and chemokines from keratinocytes and other
cells, stimulating in turn the release of pro-inflammatory cytokines
such as IL1b and IL6 from epidermal and dermal cells, causing
swelling and infiltration of leukocytes [15–18]. The predominant
effect at the early stages of the process is tissue oedema which
peaks 6 h-post treatment; this phase is followed by cell infiltration
(mainly neutrophils) which is at its highest between 12 and 24 h
[19–22]. This time course of changes was recapitulated here: at
6 h croton oil produced a marked swelling accompanied by cell
infiltration and increased MPO activity, whereas at 24 h swelling
persisted but was reduced, while cell infiltration and MPO activity
increased further.
This model has been used extensively to test novel anti-
inflammatory drugs, including glucocorticoids (e.g. dexametha-
Fig. 4. Corticosterone (B) and 5a-tetrahydrocoticosterone (5aTHB) had limited but similar effects on a variety of gene transcripts in mouse ears in a model of croton oil (CO)-
induce irritant dermatitis after 24 h. Real-time PCR analysis of transcripts for (a) inflammatory, (b) vascular and (c) extra-cellular matrix (ECM) genes in control ears (CTRL) or
ears treated for 24 h with either CO alone or together with B 5 lg or 5aTHB 25 lg. Data (mean ± SEM) were analysed with one-way ANOVA followed by Tukey’s post hoc test;
n = 10/group; p 6 0.05, # = vs CO,  = vs CTRL, £ = B vs 5aTHB.
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Fig. 5. Corticosterone (B) but not 5a-tetrahydrocorticosterone (5aTHB) dramatically reduced vessel number in a model of in vivo angiogenesis. (a) Representative
macroscopic pictures of sponges retrieved from mice after 20 days in situ, and containing either vehicle pellets (V) or pellets loaded with either B (3 mg) or 5aTHB (3 mg &
15 mg) as indicated. Representative microscopic images (magnification = 100x) of sections of sponges stained with (b) haematoxylin and eosin (H&E) or immunostained for
(c) the endothelial marker CD31 or (d) for the smooth muscle cell marker aSMA. Black arrows point either to vessels recognisable by H&E staining or positive for the marker
indicated and magnified in the corresponding inset (400x) of each image; * = examples of vessels undergoing sprouting angiogenesis. Quantification of newly formed vessels
in sponges containing either vehicle (V), B or 5aTHB and stained with (e) H&E or positive for (f) CD31 or (g) aSMA. Numbers on the x axis refer to the amount (mg) of steroids
in each sponge; data (mean ± SEM) were analysed with one-way ANOVA followed by Tukey’s post hoc test; n = 8–12 mice/group; p 6 0.05, # = vs V, * = vs B, £ = 5aTHB
3 mg vs 15 mg.
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Fig. 6. Corticosterone (B) and 5a-tetrahydrocorticosterone (5aTHB) decreased macrophage infiltration in sponges but only B reduced collagen content. Representative
microscopic images (magnification 100x) of sections of sponges stained for (a) the macrophage marker F4/80 or for (b) collagen with Picrosirius red and containing either
vehicle (V), B (3 mg) or 5aTHB (3 and 15 mg) as indicated. Black arrows in (a) point to cells expressing F4/80; the blue arrow in the inset (1000x) identifies the nucleus of a cell
negative for F4/80. Quantification of (c) cells positive for F4/80 and (d) collagen content in sponges containing either V, B or 5aTHB; numbers on the x axis refer to the amount
(mg) of steroids in each sponge. Data (mean ± SEM) were analysed with one-way ANOVA followed by Tukey’s post hoc test; n = 8–12 mice/group; p 6 0.05, # = vs V, * = B vs
5aTHB.
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effects of 5aTHB on skin inflammation were compared with those
of corticosterone, the active rodent glucocorticoid. Previous reports
of corticosterone efficacy were not available but our data suggest
that at 6 h it is twice as potent as one of the most frequently
employed topical glucocorticoids, hydrocortisone [21,27]. Notably,
the dose-dependent reduction of dermal inflammation by 5aTHB
exhibited a slower time course than corticosterone with no effect
at 6 h. Significant suppression of inflammation was, however,
achieved at 24 h, albeit requiring a 3–5 fold higher dose than cor-
ticosterone to match efficacy. This suggests that 5aTHB may pre-
dominantly target cell recruitment, which is prominent at 24 hpost CO-treatment, with neutrophils believed to be the most abun-
dant cell type present [19–22]. Analysis of MPO activity showed
that both steroids reduced neutrophil infiltration; interestingly,
this was suppressed more effectively by 5aTHB than by corticos-
terone at 24 h. The lack of response to 5aTHB to reduce swelling
at 6 h was accompanied by a failure to reduce cell number.
Experiments with the GR antagonist RU486 suggested that the
anti-inflammatory effect of B on swelling is mediated by GR. How-
ever, this seems not to be the case for 5aTHB. The fact that the anti-
inflammatory actions of 5aTHB were not antagonised by RU486
was unexpected, albeit in keeping with its different time course
of action to corticosterone. 5aTHB is a glucocorticoid metabolite,
Fig. 7. Corticosterone (B) affected gene transcripts in sponges to a greater degree than 5a-tetrahydrocorticosterone (5aTHB). Real-time PCR analysis of transcripts of (a)
vascular, (b) inflammatory and (c) extra-cellular matrix (ECM) genes in sponges containing either vehicle (V), B 3 mg or 5aTHB 3 and 15 mg as indicated. Data (mean ± SEM)
were analysed with one-way ANOVA followed by Tukey’s post hoc test; n = 8–12 mice/group; p 6 0.05, # = vs V, * = vs B, £ = 5aTHB 3 mg vs 15 mg.
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GR in vitro [28]. RU486 acts as a GR antagonist by binding to the
ligand-binding domain, blocking the recruitment of essential GR
co-activators [29,30], and if 5aTHB does operate through GR it does
so by an unconventional mechanism, perhaps through allosteric
means. Further genetic and pharmacological studies are now
required to elucidate the mechanism of action of 5aTHB.
To start to address this, the profile of action of 5aTHB was
explored further through expression profiling and compared with
responses produced by corticosterone. At 24 h, the impact of
5aTHB on expression of genes involved in regulation of inflamma-
tion and vascular homeostasis in the CO model was strikingly sim-
ilar to those of corticosterone. A noted difference was in theupregulation of Dusp1 by 5aTHB in contrast to corticosterone.
DUSP1 is a negative regulator of the MAPK signal transduction
pathway, and is increased in response to inflammatory and irritant
stimuli, leading to decreased production of cytokines, chemokines
and adhesion molecules [31,32]. A glucocorticoid-mediated
increase in its protein abundance has been reported previously in
many cell types [33–37]. DUSP1 is also upregulated by non-
steroidal anti-inflammatory compounds [32] and by new selective
modulators of GR [38]. 5aTHB and corticosterone also increased
transcripts of the anti-inflammatory gene AnxA1 (lipocortin). Lipo-
cortin was originally described as being responsible for the anti-
inflammatory properties of glucocorticoids [39], again diminishing
neutrophil recruitment by suppressing adhesion to endothelial
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many factors involved with tissue permeability and cell recruit-
ment. The effects of 5aTHB on expression of ECM proteins were
less marked than those of corticosterone, whereas both lacked
effects on transcription of most collagen genes, only decreasing
Col4a1 transcripts. Type IV collagen is one of the minor compo-
nents of the skin (less than 5%) [5], mainly forming the basement
membrane; as a consequence both steroids are likely to have little
impact on skin thickness of croton-oil treated ears after 24 h. How-
ever accurate measures of skin thickness cannot be made in the
inflamed skin in vivo. Previous in vitro microarray studies on cul-
tures of primary human keratinocytes showed that dexametha-
sone, a glucocorticoid known to cause skin thinning, decreases
transcripts of Mmp9, Mmp10, Keratin6, FilaminA and Col4a1 after
24 h incubation [40], a profile similar to that of corticosterone in
our model.
Two of the major side effects of topical anti-inflammatory glu-
cocorticoids are skin thinning and delayed wound healing, requir-
ing careful assessment of potential adverse effects for any
proposed topical steroid therapy. Angiogenesis and collagen turn-
over are important factors in skin homeostasis, with angiogenesis
particularly important for dermal healing [41]. Following the
demonstration that cortisone inhibits angiogenesis in vitro, a num-
ber of ‘‘angiostatic steroids” have been identified [42]. These
include 5b-tetrahydrocortisol, one of the A-ring reduced metabo-
lites of cortisol (the major glucocorticoid in humans). Here the
impact of 5aTHB on angiogenesis, inflammation and collagen
deposition was studied in response to implantation of subcuta-
neous sponges [43]. This model is steroid sensitive [44] and
equipotent anti-inflammatory doses of corticosterone and 5aTHB
(based on results from the croton-oil model) were administered
in the sponges. 5aTHB reduced angiogenesis but to a lesser degree
than, and with a different pattern to, corticosterone. It was notable
that both compounds reduced vessel density, predominantly by
reducing the number of CD31-positive vessels. However, unlike
corticosterone, 5aTHB did not reduce the number of aSMA positive
vessels. CD31-staining identifies endothelial cells lining vascular
structures and can be used to detect small (capillaries) and larger
vessels [45]. In contrast, aSMA, staining detects pericytes and
smooth muscle cells, and can be used to identify larger/maturing
vessels with a functional medial layer [46]. Thus, these results sug-
gest that, although 5aTHB does reduce new vessel formation, it
does not adversely affect the number of mature vessels and, hence,
may be less likely to attenuate wound healing. Caveats do, how-
ever, apply in that retention of 5aTHB and corticosterone within
sponges was not directly compared in this study.
In terms of local inflammation, both corticosterone and 5aTHB
inhibited macrophage infiltration. Inflammatory cells, in particular
monocytes/macrophages, are central players in angiogenesis as
they are a source of pro-angiogenic cytokines [47]. Indeed, it is
often difficult to distinguish between direct angiostatic properties
and those that are a consequence of reduced inflammation. In the
croton oil model there was a bigger effect of 5aTHB compared to
corticosterone on neutrophil infiltration, whereas this is not true
regarding the recruitment of macrophages analysed in the angio-
genesis model. This suggests that neutrophils might be the prefer-
ential cellular target for 5aTHB in an inflammatory setting.
Importantly, macrophages have a pivotal role in wound repair
[41], and a compound with fewer inhibitory effects on their infil-
tration might be more desirable.
Relatively few changes in gene transcripts for factors that regu-
late aspects of vascular function were consistent with 5aTHB hav-
ing a limited effect on the developing vasculature, with only a
modest reduction in Pecam1 which support the immunostaining
data for CD31. In contrast, corticosterone inhibited expression of
most of the factors assessed (Icam1, Pecam1, VE-cadherin, E-selectin and Acta2), consistent with its potent anti-angiogenic prop-
erties [44], and again reinforce the data obtained with the
immunostaining of CD31 and aSMA in sponge sections. These fac-
tors contribute to stabilisation of cell-cell contact between
endothelial cells [45], and the dynamics of cell rearrangement cen-
tral to vessel formation [48,49]. The only exceptions were the
increased expression of Vegfa and Vcam1. Vegfa has a key role in
stimulating angiogenesis [50–52], so would be expected to be
reduced by corticosterone (although it is possible that the
increased expression is a consequence of insufficient angiogenesis
in the sponges). However, this was accompanied by reduced Vegfr2
transcript number, consistent with inhibition of angiogenesis seen
in previous studies with other glucocorticoids [53]. VEGFR2 is the
main receptor responsible for the majority of the effects of VEGF on
endothelial cells [53] and is associated with proliferation of new
vessels during wound healing [53].
Intriguingly, despite its potent anti-inflammatory properties,
corticosterone only produced a small reduction in transcripts of
pro-inflammatory genes. 5aTHB, despite reducing macrophage
infiltration, did not reduce expression of any of the transcripts
analysed and, indeed, increased abundance of transcripts of
Mcp1. A similar induction of Mcp1/MCP1 promoted vessel growth
in infarcted hearts in mice [54], suggesting this may be a compen-
satory mechanism in response to an ischemic event. In previous
studies of peritonitis 5aTHB also suppressed inflammatory cell
recruitment, but with a more profound effect on neutrophils com-
pared with macrophages [7].
The extra-cellular matrix (ECM) plays a vital role in wound
healing and many studies show that glucocorticoids cause skin
damage by depleting collagen isoforms [55]. This again could be
modelled in the implanted sponges with consistent reductions in
collagen deposition and expression of the four collagen isoform
transcripts analysed in corticosterone-treated sponges. Impor-
tantly, 5aTHB had little effect on collagen staining, significantly
reducing only Col1a2 expression. Skin collagen fibrils are made
mostly of type 1 collagen, a heterodimer composed by three alpha
chains, two encoded by Col1a1 and one by Col1a2 [5]. The lack of
effects on Col1a1 transcripts by 5aTHB might explain why this
compound did not affect the overall collagen content in sponges.
Furthermore, the absence of effect on Col4a1 transcripts suggest
a reduced impact, compared to corticosterone, on angiogenesis,
as type IV collagen is a major component of the basement mem-
brane (facilitating the differentiation of endothelial cells during
formation of capillary-like structures) [56]. This contrasts with
the dermatitis model where both steroids had a small effect to
reduce Col4a1, but over a shorter time course. Metalloproteinase
enzymes (MMPs) influence wound healing, predominantly by pro-
moting ECM degradation and cell migration [57], whereas tissue
inhibitors of MMPs (TIMPs) oppose these actions. Corticosterone,
but not 5aTHB, decreased expression of MMPs (Mmp10 and
Mmp2) within the sponges, which may contribute to alterations
in matrix composition and to inhibition of angiogenesis [58,59].
Studies of mechanism in the croton oil and sponge model were
mainly limited to analysis of transcript abundance, due to paucity
of tissue. While complementary analysis confirmed effects on
CD31 (Pecam1), aSMA (Acta2) and collagen protein, GCs have been
shown to inhibit translation rather than transcription for some
molecules involved in inflammation [60,61]. As a consequence,
while no significant effect of 5aTHB or B was found on transcrip-
tion of cytokines, it remains possible that they may be affecting
the translation of those transcripts.
In conclusion, 5aTHB is an effective topical anti-inflammatory
steroid, reducing acute skin inflammation possibly binding to a dif-
ferent receptor than GR. Its limited effects on angiogenesis and de
novo deposition of collagen (combined with previous reports of its
rapid systemic elimination and, therefore, reduced metabolic side-
A. Gastaldello et al. / Biochemical Pharmacology 129 (2017) 73–84 83effects), suggest it may have potential as a novel topical anti-
inflammatory treatment and careful dissection of its mechanism
of action is now required.
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